1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6699D7EB3EFF331CB00258AAE00329A7A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/oncology-field-medical-excellence-benchmark-top-12-global-markets-establishing-standards-high-performance-impact
18
19
20172.69.7.142
21
22
23116639.0ncwlf7ax.asia
24/bestp/domrep.nsf
25BMR
Access. Intelligence. Excellence

| Advanced Search | 0
Research and Consulting Areas of Expertise

Benchmarking Reports Areas of Expertise Report Catalog FAQ
Best Practice Database Areas of Expertise New Research Case Analogs Benefits Types Of Research Current Members
Research and Advisory Services Areas of Expertise Digital Technology Consortium Field Medical Excellence Medical Affairs Consortium White Papers Research Partners Partnership Benefits Contact Us
Excellence Services Pharma and Medical Device Quality New Product Planning Medical Affairs Pharmaceutical Launch Market Research Competitive Intelligence

Industries

Biotechnology Financial Services Healthcare Medical Device Manufacturing Pharmaceuticals Technology and Communications

Functions

Brand Management & Product Leadership Competitive & Business Intelligence Commercial Operations Customer Service Clinical Operations Digital Technologies / AI Human Resources Medical Affairs Market Access Market Research, Analytics & Forecasting

 

Marketing Management Patient Access, Support, Insights and Operations Product Launch Pull Through Pharma Launch Playbook Scenario Planning / War Gaming Sales Supply Chain
Corporate Overview About Benchmarking Benchmarking Books What is a Best Practice? Research Methodology

Our Clients Testimonials

Our Team Careers Best Practices Interns Work at Best Practices, LLC Help Set Research Agenda
Follow Best Practices LLC linkedIn twitter slideshare youtube pinterest

Overview Press Releases Speaking Events Media Coverage Receive Research Updates Contact Us
Address/Email/Phone Schedule a Meeting
Report Catalog Videos
Database Member Home RAS Member Home

» Products & Services » » Medical Affairs » Field Medical Excellence

Oncology Field Medical Excellence Benchmark of Top 12 Global Markets: Establishing Standards for High Performance & Impact

Oncology Field Medical Excellence Benchmarks

Download FREE Excerpt

ID: POP-372

Features:

10 Info Graphics

51 Data Graphics

440+ Metrics

7 Narratives

Pages: 70

Published: 2024

Delivery Format: Shipped

 

License Options:


Buy Now

 

919-403-0251
Schedule a Meeting

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
As Oncology manufacturers expand their operations globally, field medical leaders encounter a myriad of challenges in delivering top-tier support to diverse local teams. In order to better establish overarching "Global Standards for Field Performance," Oncology field medical leadership will benefit from identifying key performance indicators, competitor frameworks, benchmarks for effective field coverage, and impactful strategies for advising local teams.

Best Practices, LLC undertook this benchmarking research to empower Oncology Field Medical Excellence leaders in crafting a framework that fosters consistency and high impact across five major regions worldwide — North America, Europe, APAC, LATAM, and MENA. Utilizing a comprehensive dataset meticulously segmented at regional levels, our report serves as an indispensable resource for field medical leaders. It delivers strategic insights to enhance KOL interactions, assess MSL performance, and strategically align staffing footprints. In essence, the report offers an insightful roadmap for optimizing Oncology field medical operations on a global scale.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

Study Snapshot

Best Practices, LLC collated performance data and insights from Field Medical executives from Oncology companies around the world through a custom benchmark survey. Focused on Oncology field medical operations, the research drew insights from a diverse range of respondents and was meticulously segmented at regional levels.

Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks for maximal alignment with varied portfolio considerations.

The final study draws on 448 survey responses, representing a benchmark class of over 100 biopharma manufacturers.

Key topics covered in this report include:

  • Effective Oncology Field Performance Metrics
  • Building an Oncology Field Medical Excellence Framework
  • Target and Engagement Levels of Key Opinion Leaders in the Oncology Segment
  • Average Time Oncology MSLs Spend on KOL Interactions and Internal Activities
  • Oncology Field Medical Staffing Footprint
  • Key Insights and Lessons Learned for Measuring the Impact of Oncology MSLs

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.
  • Emphasis on F2F Interactions in North America: Within the North American Oncology field medical teams, a notable trend emerges as half of the teams assign higher value to Face-to-Face (F2F) interactions, recognizing their significant impact on the overall MSL scorecard.
  • Time Spent on External Engagement: Oncology Medical Science Liaisons (MSLs) in LATAM dedicate slightly over half of their time (52%) to direct external engagement. In MENA, Oncology MSLs allocate the highest portion of their time (63%) to direct external engagement.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive Summary: Laying the Foundation for Global Field Medical Performance Standards & Expectations in OncologyPg. 3-19
II.
North America: Regional Data Segmented by Oncology Therapeutic AreaPg. 20-29
III.
Europe: Regional Data Segmented by Oncology Therapeutic AreaPg. 30-39
IV.
APAC: Regional Data Segmented by Oncology Therapeutic AreaPg. 40-49
V.
LATAM: Regional Data Segmented by Oncology Therapeutic AreaPg. 50-59
VI.
MENA: Regional Data Segmented by Oncology Therapeutic AreaPg. 60-69
VII.
About Best Practices, LLCPg. 70

    List of Charts & Exhibits

    I. Executive Summary: Laying the Foundation for Global Field Medical Performance Standards & Expectations in Oncology

    • Business objectives and research methodology
    • Regions and therapeutic areas probed in this benchmark research
    • Participating benchmark companies
    • Global benchmarking findings: Quick takeaways and recommendations
    • Global benchmarking findings: Summary of Oncology regional data
    • Global field scorecard: Benchmarking Oncology engagement metrics across all five regions
      Most effective and utilized field metrics for assessing and showcasing the value of MSLs
    • Metrics to evaluate MSL performance
    • Lessons learned around MSL time allocation in field and on external activities
    • Defining “monthly interactions”
    • Distinguishing an "actionable" insight from other kinds of insights
    • Definitions of "actionable insights" from the field
    • Crafting a global framework for excellence in field medical engagement

    II. North America: Regional data segmented by Oncology Therapeutic Area

    • North America field scorecard: Benchmarking Oncology engagements
    • Average number of tiered vs. non-tiered KOLs per Oncology MSL in North America
    • Monthly KOL and F2F interactions in North America – Oncology segment
    • Weighting criteria for various interaction types on the Oncology MSL scorecard (North America)
    • Metrics for engaging non-tiered Oncology KOLs in North America
    • Average Oncology MSL time in the field (days per year) in North America
    • Percentage of Oncology MSL time spent on external, internal, and logistics activities in North America
    • Weekly Oncology MSL time allocation for each activity stream in North America
    • Percentage of overall Oncology targets classified as KOLs, HCPs, payers, or other external stakeholders in North America
    • Oncology field medical staffing footprint in North America

    III. Europe: Regional data segmented by Oncology Therapeutic Area

    • Europe field scorecard: Benchmarking Oncology engagements
    • Average total panel size supported by an Oncology MSL in Europe
    • Average number of monthly KOL/HCP and F2F meetings in Europe – Oncology segment
    • Value assigned to each interaction type on the Oncology MSL scorecard (Europe)
    • Engagement metrics for non-tiered Oncology KOLs in Europe
    • Average annual field presence of Oncology MSLs in Europe
    • Time spent by Oncology MSLs on external, internal, and logistics activities in Europe
    • Weekly Oncology MSL time allocation across activity streams in Europe
    • Oncology MSL engagement mix in Europe
    • Oncology field medical staffing footprint in Europe

    IV. APAC: Regional data segmented by Oncology Therapeutic Area

    • APAC field scorecard: Benchmarking Oncology engagements
    • Average number of tiered vs. non-tiered KOLs per Oncology MSL in the APAC region
    • Monthly KOL and F2F interactions in the APAC region – Oncology segment
    • Weighting criteria for various interaction types on the Oncology MSL scorecard (APAC region)
    • Metrics for engaging non-tiered Oncology KOLs in the APAC region
    • Average Oncology MSL time in the field (days per year) in the APAC region
    • Percentage of Oncology MSL time spent on external, internal, and logistics activities in the APAC region
    • Weekly Oncology MSL time allocation for each activity stream in the APAC region
    • Percentage of overall Oncology targets classified as KOLs, HCPs, payers, or other external stakeholders in the APAC region
    • Oncology field medical staffing footprint in the APAC region

    V. LATAM: Regional data segmented by Oncology Therapeutic Area

    • LATAM field scorecard: Benchmarking Oncology engagements
    • Average number of tiered vs. non-tiered KOLs per Oncology MSL in the LATAM region
    • Monthly KOL and F2F interactions in the LATAM region – Oncology segment
    • Weighting criteria for various interaction types on the Oncology MSL scorecard (LATAM region)
    • Metrics for engaging non-tiered KOLs in the LATAM region
    • Average Oncology MSL time in the field (days per year) in the LATAM region
    • Percentage of Oncology MSL time spent on external, internal, and logistics activities in the LATAM region
    • Weekly Oncology MSL time allocation for each activity stream in the LATAM region
    • Percentage of overall Oncology targets classified as KOLs, HCPs, payers, or other external stakeholders in the LATAM region
    • Oncology field medical staffing footprint in the LATAM region

    VI. MENA: Regional data segmented by Oncology Therapeutic Area

    • MENA field scorecard: Benchmarking Oncology engagements
    • Average total panel size supported by an individual Oncology MSL in the MENA region
    • Average number of monthly KOL/HCP and F2F meetings in the MENA region
    • Value assigned to each interaction type on the Oncology MSL scorecard (MENA region)
    • Engagement metrics for non-tiered KOLs in the MENA region
    • Average annual field presence of Oncology MSLs in the MENA region
    • Time spent by Oncology MSLs on external, internal, and logistics activities in the MENA region
    • Weekly Oncology MSL time allocation across activity streams in the MENA region
    • Oncology MSL engagement mix in the MENA region
    • Average number of Oncology field staff members in the MENA region

    RELATED RESEARCH